Vindico Pharmaceuticals, based in Lexington KY, is a privately-held biotechnology company that is dedicated to the discovery, development and commercialization of highly innovative products for a wide range of diagnostic and therapeutic applications. Its product pipeline is based on a nanometer-scale particulate technology known as the polymersome. Polymersomes are nanovesicles (“hollow sacks”) that are comprised entirely of FDA-approved biodegradable polymers that spontaneously self-assemble in water. Compared to other nanocarriers, polymersomes have several distinct advantages including larger loading capacities and superior formulation stabilities. As such, polymersomes are particularly useful for the stable encapsulation of both water-soluble and insoluble agents, in high concentration, without the need for chemical modification of their cargo. They have successfully been used to deliver a wide variety of agents, including small molecules, peptides, proteins, and nucleic acids for diagnostic and therapeutic applications. Further, polymersomes’ unique structural properties enable specific delivery to target sites without concomitant loss of their cargo due to premature breakdown after prolonged shelf-storage or in high shear flow, in vivo vascular environments.
Vindico’s primary focus is on the development of in vitro diagnostics and in vivo therapeutics in the transfusion medicine market. The use of our products will result in significant advances and improvements in the standard of patient care. They will also result in considerable reduction in the time and cost of health-care delivery. Owing to the enormous versatility of the polymersome architecture, Vindico’s technologies also have broad utility for other applications including as delivery vehicles for chemotherapeutics and vaccines as well as for diagnostic agents capable of both in vitro and in vivo molecular imaging of infectious, immunologic, and oncologic processes.